Karen Gilchrist

Business and Finance Correspondent based in London. Formerly @CNBCi in London and Singapore. Views my own.

[Karen Gilchrist @_karengilchrist]

My first @CNBCi Digital Original! Following #Russia’s invasion of #Ukraine, a spotlight has been cast on #London's complicity as a store for #dirtymoney. Now, the U.K. is seeking to salvage its reputation with a new clampdown on corruption. But will it be successful? I explore.

[Karen Gilchrist @_karengilchrist]

Such an inspiring evening hearing from @WomenforWomen and @camourlevar about the incredible work they’re doing for marginalised women #womenforwomeninternational

[Karen Gilchrist @_karengilchrist]

My latest for @MorningstarInc: Higher Jet Fuel Costs Spell Fresh Uncertainty for European Airline Stocks https://t.co/BoMFgl1qt4

[Karen Gilchrist @_karengilchrist]

H&M shares popped 10% on Thursday on better-than-expected fiscal third quarter results and as CEO Daniel Ervér's turnaround strategy showed signs of gaining pace.

[Karen Gilchrist @_karengilchrist]

Roche targets becoming top 3 obesity player as experimental drug enters late-stage trial https://t.co/wotN1nxeIG

[Karen Gilchrist @_karengilchrist]

UK's GSK announces $30 billion U.S. pharma investment amid Trump state visit https://t.co/PpqJA7VQQO

[Karen Gilchrist @_karengilchrist]

Novo Nordisk flags drug trial promise amid hunt for next weight-loss blockbuster https://t.co/kRnC3Iwdnm

[Karen Gilchrist @_karengilchrist]

Pharma firms pile pressure on the UK as Trump's drug pricing order looms https://t.co/EU48me6FLG

[Karen Gilchrist @_karengilchrist]

Swatch takes a swipe at Trump’s 39% tariff with switched-up watch https://t.co/xABp3UB07c

[Karen Gilchrist @_karengilchrist]

Fascinating read from @LeeYingShan on Singapore's wealth clampdown -- Rich Chinese are exiting Singapore as wealth regulations tighten: 'my patience is gone' https://t.co/KqJWmGiXWm

[Karen Gilchrist @_karengilchrist]

New from my on @CNBCi: Luxury brands bet on $160 lipsticks and $1,400 accessories to combat industry slump https://t.co/ot9jCFEnE8

[Karen Gilchrist @_karengilchrist]

Spanish retail giant and Zara owner @Inditex posted weaker-than-expected second-quarter sales on Wednesday, but flagged an uptick in current trading.

Shares jumped more than 7% in early trading.

#retail #sales #Inditex #earnings #Zara #MassimoDutti #Bershka #clothes #consumer

[Karen Gilchrist @_karengilchrist]

How Italy's flat-tax regime has sparked a super-rich boom

[Karen Gilchrist @_karengilchrist]

Italy — a perennial favorite of the rich and famous — is attracting a new wave of ultra-wealthy arrivals looking to take advantage of its investor friendly environment, thriving real estate market and low tax regime https://t.co/ylpoOAbrDw

[Karen Gilchrist @_karengilchrist]

💉A world on weight loss drugs: How GLP-1s are reshaping the economy https://t.co/jlwCgFtUpY

[Karen Gilchrist @_karengilchrist]

U.S. and EU spell out tariffs for autos, pharmaceuticals, and more https://t.co/7hDEcdzPsd

[Karen Gilchrist @_karengilchrist]

Shein’s China pivot is a last-ditch bid to rescue its IPO, analysts say https://t.co/wPvpehv82A

[Karen Gilchrist @_karengilchrist]

Eli Lilly's 170% UK price hike for Mounjaro is just the start as pharma firms bow to Trump's pricing pressures https://t.co/U7Etxh5BCz

[Karen Gilchrist @_karengilchrist]

'Loud luxury' is back as high-end brands look to rebound https://t.co/LYtmi4WChK

[Karen Gilchrist @_karengilchrist]

Novo Nordisk doubles down on Trump-friendly sales strategy https://t.co/KEq6xwKjZW

[Karen Gilchrist @_karengilchrist]

Wegovy-maker @novonordisk said Wednesday that it's doubling down on direct-to-consumer sales as it contends with copycat compounders and Washington's demands for lower domestic drug prices